Intra-Cellular Therapies, Inc. (ITCI)
| Previous Close | 74.01 |
| Open | 73.71 |
| Bid | 72.68 x 100 |
| Ask | 73.34 x 200 |
| Day's Range | 72.41 - 73.97 |
| 52 Week Range | 45.50 - 84.89 |
| Volume | |
| Avg. Volume | 973,385 |
| Market Cap | 7.623B |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 91.91 |
Insider Monkey10 Best Performing Biotech ETFs in 2024
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
GlobeNewswireIntra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share. All of the shares in the offering will be sold by Intra-Cellular Ther
Investor's Business DailyBiotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point
Intra-Cellular stock: Shares rocketed more than 23% Tuesday, sending them past their latest buy point on the stock market today.
